Evogene (NASDAQ:EVGN) Stock Crosses Below 200-Day Moving Average – Should You Sell?

Evogene Ltd. (NASDAQ:EVGN)’s stock price passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $1.19 and traded as low as $1.03. Evogene shares last traded at $1.0550, with a volume of 31,891 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Evogene in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $3.50.

Evogene Stock Performance

The stock has a market capitalization of $5.67 million, a P/E ratio of -2.11 and a beta of 1.28. The company’s fifty day simple moving average is $1.07 and its two-hundred day simple moving average is $1.19.

Evogene (NASDAQ:EVGN) last issued its quarterly earnings data on Thursday, November 20th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.10. Evogene had a negative return on equity of 75.09% and a negative net margin of 52.33%.The company had revenue of $0.31 million during the quarter, compared to analysts’ expectations of $0.65 million.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Evogene stock. Citadel Advisors LLC grew its position in shares of Evogene Ltd. (NASDAQ:EVGN) by 169.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 57,575 shares of the biotechnology company’s stock after buying an additional 36,206 shares during the period. Citadel Advisors LLC owned approximately 1.07% of Evogene worth $66,000 at the end of the most recent quarter. 10.40% of the stock is owned by institutional investors and hedge funds.

About Evogene

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.